ALIMTA is not indicated for treatment of patients with squamous cell NSCLC. Myelosuppression is usually the dose-limiting toxicity with ALIMTA therapy.About Non-Small Cell Lung Cancer (NSCLC)Lung cancer has long been the most common cancer in the world, representing nearly 13 percent of all new cancers and causing nearly 1.4 million deaths annually. 2 About 85 percent of all lung cancers are NSCLC. 3 The liver, bones and brain are potential targets if the cancerous cells spread to other areas in the body. NSCLC comprises a group of histologies or tumor types differentiated by cellular structure. Nonsquamous histology includes adenocarcinoma and large cell carcinoma, which account for more than half of all NSCLC diagnoses, 4 as well as histologies classified as "other." About Lilly OncologyFor more than four decades, Lilly Oncology, a division of Eli Lilly and Company, has been dedicated to delivering innovative solutions that improve the care of people living with cancer. Because no two cancer patients are alike, Lilly Oncology is committed to developing novel treatment approaches. To learn more about Lilly's commitment to cancer, please visit www.LillyOncology.com. About Eli Lilly and CompanyLilly, a leading innovation-driven corporation, is developing a growing portfolio of pharmaceutical products by applying the latest research from its own worldwide laboratories and from collaborations with eminent scientific organizations. Headquartered in Indianapolis, Ind., Lilly provides answers – through medicines and information – for some of the world's most urgent medical needs. P-LLY Consumer Important Safety Information (ISI) Important Safety Information for ALIMTA® (pemetrexed for injection) What is the most important information that I should know about ALIMTA?ALIMTA can suppress bone marrow function, which may cause low blood cell counts. ALIMTA may not be appropriate for some patients.